Top entities: Lateral Pharma, David Kenley, PAIN (journal), Pacific Discovery Services, Evotec.

What category does this event fall under?

Tech — classified as medical breakthrough.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Lateral Pharma announced publication PAIN (journal) · Lateral Pharma conducted Phase 1b study · United States — United States Patent and Trademark Office granted patent Lateral Pharma

Is this event still developing?

This is an active story, last updated Jun 12, 2026. Coverage continues to evolve.

Tech medical breakthrough

Lateral Pharma identifies neuropathic pain target

Q: When did this event occur?

First reported Jun 11, 2026; last updated Jun 12, 2026.

Q: What is the market impact?

Direct. The publication of this research by Lateral Pharma validates its Stressed Cell Protectant platform and its SCP drugs, particularly LAT8881 and LAT9997, for neuropathic pain and other conditions.

Analysis based on 10 articles · First reported Jun 11, 2026 · Last updated Jun 12, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The publication of this research by Lateral Pharma validates its Stressed Cell Protectant platform and its SCP drugs, particularly LAT8881 and LAT9997, for neuropathic pain and other conditions. This positive scientific validation and the granted patent by the United States — United States Patent and Trademark Office could significantly increase investor confidence in Lateral Pharma, potentially leading to higher valuations and future investment opportunities in the biotechnology sector.

Biotechnology Pharmaceuticals

Event Summary

Lateral Pharma announced the publication of peer-reviewed research in PAIN (journal), identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. This research demonstrates that Lateral Pharma's Stressed Cell Protectant (SCP) drugs, including LAT8881 and LAT9997, act via LanCL1. The findings are consistent with Lateral Pharma's Phase 1b study, which showed LAT8881 was safe, well-tolerated, and reduced pain in patients with chronic lumbar radicular pain. Additionally, LAT9997 showed significant improvement in survival and reduced lung injury in preclinical models of influenza-associated bacterial pneumonia. The United States — United States Patent and Trademark Office has also granted a patent covering LAT9997 for neuropathic pain. David Kenley, CEO of Lateral Pharma, emphasized the importance of this milestone for addressing unmet medical needs.

Key Actions

100 Lateral Pharma announced publication PAIN (journal)

80 Lateral Pharma conducted Phase 1b study

70 United States — United States Patent and Trademark Office granted patent Lateral Pharma

Entities Involved

priv

Lateral Pharma

Lateral Pharma announced the publication of peer-reviewed research identifying LanCL1 as a novel therapeutic target for neuropathic pain, responsive to its SCP drugs. This validates their Stressed Cell Protectant platform and supports continued development of SCPs, potentially increasing its valuation and future market position.

Importance 100 Sentiment 75

per

David Kenley

David Kenley, CEO of Lateral Pharma, highlighted the significance of the publication as a pivotal milestone for advancing neuropathic pain biology and accelerating Lateral Pharma's mission.

Importance 50 Sentiment 0

oth

PAIN (journal)

PAIN, a leading journal dedicated to pain research, published the peer-reviewed research from Lateral Pharma, lending credibility to the findings.

Importance 30 Sentiment 10

priv

Pacific Discovery Services

Pacific Discovery Services was among the organizations whose researchers co-authored the publication.

Importance 15 Sentiment 10

stock

Evotec

Evotec was among the organizations whose researchers co-authored the publication.

Importance 15 Sentiment 10

govactor

United States — United States Patent and Trademark Office

The United States — United States Patent and Trademark Office granted a composition-of-matter patent covering LAT9997 for the treatment of neuropathic pain, reinforcing Lateral Pharma's intellectual property.

Importance 10 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard